Pascal Deschatelets - 14 Nov 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
14 Nov 2023
Net transactions value
+$169,200
Form type
4
Filing time
15 Nov 2023, 16:10:16 UTC
Previous filing
09 Nov 2023
Next filing
17 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $169,200 +45,000 +4.2% $3.76 1,116,807 14 Nov 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -45,000 -20% $0.000000 175,494 14 Nov 2023 Common Stock 45,000 $3.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was granted on 02/08/2016 and is fully vested.